Comparing Revenue Performance: Vertex Pharmaceuticals Incorporated or Travere Therapeutics, Inc.?

Vertex vs. Travere: A Decade of Revenue Growth

__timestampTravere Therapeutics, Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 201428203205580415000
Thursday, January 1, 2015998920001032336000
Friday, January 1, 20161335910001702177000
Sunday, January 1, 20171549370002488652000
Monday, January 1, 20181642460003047597000
Tuesday, January 1, 20191753380004162821000
Wednesday, January 1, 20201983210006205683000
Friday, January 1, 20212274900007574400000
Saturday, January 1, 20222120180008930700000
Sunday, January 1, 20231452380009869200000
Monday, January 1, 202411020100000
Loading chart...

In pursuit of knowledge

A Decade of Revenue Growth: Vertex vs. Travere

In the competitive landscape of pharmaceuticals, revenue growth is a key indicator of success. Over the past decade, Vertex Pharmaceuticals Incorporated has demonstrated a remarkable upward trajectory in revenue, growing from approximately $580 million in 2014 to nearly $9.9 billion in 2023. This represents an impressive increase of over 1,600%. In contrast, Travere Therapeutics, Inc. has seen a more modest growth, with revenue rising from about $28 million in 2014 to $145 million in 2023, marking a 417% increase.

Key Insights

Vertex's consistent revenue growth highlights its strong market position and successful product pipeline. Meanwhile, Travere's steady increase, though smaller in scale, indicates a growing presence in the industry. This comparison underscores the diverse strategies and market dynamics at play in the pharmaceutical sector, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025